We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AI Algorithm Combined With Blood Test Quickly and Accurately Diagnoses Heart Attacks in Women

By LabMedica International staff writers
Posted on 05 Sep 2022
Print article
Image: Artificial intelligence could help narrow heart attack gender gap (Photo courtesy of Unsplash)
Image: Artificial intelligence could help narrow heart attack gender gap (Photo courtesy of Unsplash)

Previous research has shown that women in the UK who have a heart attack receive poorer care than men at every stage. Women were 50% more likely to receive a wrong initial diagnosis, highlighting the need for innovations to help close the heart attack gender gap. Measuring the protein troponin in the blood is the current gold standard for diagnosing a heart attack. However, the levels of troponin released by the heart vary between men and women, with age and other health conditions. Current guidelines use the same threshold for all patients, meaning current tests are not as accurate as they could be. Now, an algorithm developed using artificial intelligence (AI) could help doctors to diagnose heart attacks in women more accurately and quicker than ever before.

Researchers at the University of Edinburgh (Edinburgh, Scotland) combined data from 10,038 people (48% women) who went to hospital with a suspected heart attack to develop an AI-based tool to help clinicians diagnose heart attacks more accurately. They then validated it on a further 3,035 people (31% women) outside of the UK. The tool, called CoDE-ACS, uses AI to combine routinely collected patient information when they arrive at hospital (including sex, age, observations, ECG findings and medical history) with the results from the troponin blood test. This then produces a score of 0 to 100.

The team found that CoDE-ACS was able to rule out a heart attack with 99.5% accuracy, confirming they were safe to go home. It also identified those who would benefit from staying in hospital for further tests, in whom the final diagnosis was a heart attack, with an accuracy of 83.7%. This compares to an accuracy of just 49.4% with current tests. Fewer than half of those identified for further testing using current approaches had a diagnosis of heart attack. The performance of the tool was consistent regardless of sex, age and pre-existing health conditions. Current tests mean that some patients’ troponin levels do not fit into the ‘rule in’ or ‘rule out’ thresholds, making clinical decisions more challenging. However, with a second troponin measurement, CoDE-ACS was able refine risk in the 29.5% of people who did not fit the simple ‘rule in’ or ‘rule out’ criteria allowing accurate determination if further action was needed.

“This is a huge step forward which promises to ensure everyone is on a level playing field when it comes to heart attack diagnosis and treatment,” said Professor James Leiper, our Associate Medical Director. “We know that women are more likely to receive a misdiagnosis, but by harnessing the power of AI, this team could provide one solution that helps to make that an issue of the past.”

“We’ve now embedded our algorithm into an easy-to-use mobile app to support doctors in guiding treatment decisions,” said Dimitrios Doudesis, data scientist at the BHF Centre for Cardiovascular Science, University of Edinburgh. “Whilst the troponin test takes 30 minutes to process, we take an array of other health information and add it into the app alongside the troponin measurement. This provides doctors with a precise and instantaneous score to confirm if they can reassure their patient that they haven’t had a heart attack and send them home, or if they require further tests.”

Related Links:
University of Edinburgh

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.